Search results for "Tobramycin"

showing 10 items of 24 documents

Role of AxyZ Transcriptional Regulator in Overproduction of AxyXY-OprZ Multidrug Efflux System in Achromobacter Species Mutants Selected by Tobramycin

2017

ABSTRACT AxyXY-OprZ is an RND-type efflux system that confers innate aminoglycoside resistance to Achromobacter spp. We investigated here a putative TetR family transcriptional regulator encoded by the axyZ gene located upstream of axyXY-oprZ . An in-frame axyZ gene deletion assay led to increased MICs of antibiotic substrates of the efflux system, including aminoglycosides, cefepime, fluoroquinolones, tetracyclines, and erythromycin, indicating that the product of axyZ negatively regulates expression of axyXY-oprZ . Moreover, we identified an amino acid substitution at position 29 of AxyZ (V29G) in a clinical Achromobacter strain that occurred during the course of chronic respiratory tract…

0301 basic medicineAchromobacterCefepime030106 microbiologyPopulationAchromobacterMicrobial Sensitivity TestsBiologymedicine.disease_causeMicrobiology03 medical and health scienceschemistry.chemical_compoundAntibiotic resistanceBacterial ProteinsMechanisms of ResistanceDrug Resistance Multiple BacterialTobramycinmedicineHumansPharmacology (medical)TetRAmino Acid Sequence[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]educationComputingMilieux_MISCELLANEOUSPharmacologyeducation.field_of_studyPseudomonas aeruginosaMembrane Transport Proteins[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyGene Expression Regulation Bacterialbiology.organism_classification[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyAnti-Bacterial Agents3. Good healthInfectious DiseasesAmino Acid SubstitutionchemistryPseudomonas aeruginosaTobramycinTrans-ActivatorsEffluxGene DeletionBacterial Outer Membrane Proteinsmedicine.drugAntimicrobial Agents and Chemotherapy
researchProduct

Negative Impact of Citral on Susceptibility of Pseudomonas aeruginosa to Antibiotics

2021

Essential oils (EOs) or their components are widely used by inhalation or nebulization to fight mild respiratory bacterial infections. However, their interaction with antibiotics is poorly known. In this study we evaluated the effects of citral, the main component of lemongrass oil, on in vitro susceptibility of Pseudomonas aeruginosa to antibiotics. Exposure of strain PA14 to subinhibitory concentrations of citral increased expression of operons encoding the multidrug efflux systems MexEF-OprN and MexXY/OprM, and bacterial resistance to anti-pseudomonal antibiotics including imipenem (twofold), gentamicin (eightfold), tobramycin (eightfold), ciprofloxacin (twofold), and colistin (≥128-fold…

0301 basic medicineMicrobiology (medical)antibiotic resistancemedicine.drug_class[SDV]Life Sciences [q-bio]030106 microbiologyAntibioticsmedicine.disease_causeCitralMicrobiologyMicrobiology03 medical and health scienceschemistry.chemical_compoundtobramycin-citral Schiff baseTobramycinmedicine[CHIM]Chemical Sciencesessential oilscitralOriginal ResearchPseudomonas aeruginosaChemistryAminoglycosidecolistin-citral Schiff baseSciences du Vivant [q-bio]/Microbiologie et Parasitologie[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyeffluxQR1-5023. Good health030104 developmental biology[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyPseudomonas aeruginosaColistin[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyGentamicinEfflux[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.drugFrontiers in Microbiology
researchProduct

Re: Antimicrobial Resistance in More Than 100,000 Escherichia coli Isolates According to Culture Site and Patient Age, Gender, and Location

2011

ABSTRACT Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in…

AdultMaleCefotaximeAdolescentmedicine.drug_classUrologyAntibioticsCefotaximeDrug resistanceFosfomycinBiologymedicine.disease_causeEpidemiology and SurveillanceMicrobiologyYoung AdultAntibiotic resistanceFosfomycinCiprofloxacinPatient ageDrug Resistance Multiple BacterialEscherichia coliHumansMedicinePharmacology (medical)ChildAmikacinEscherichia coliEscherichia coli InfectionsAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologybusiness.industryInfantMiddle AgedAntimicrobialAnti-Bacterial AgentsImipenemInfectious DiseasesNitrofurantoinAmikacinChild PreschoolTobramycinAmpicillinFemalebusinessmedicine.drugJournal of Urology
researchProduct

Selection of optimal prophylactic aminoglycoside dosage in cancer patients: population pharmacokinetic approaches.

1994

We report an alternative dose-finding approach for the selection of optimal prophylactic aminoglycoside dosage in specific (sub)populations of patients. Relative a priori utility of several intervals of gentamicin or tobramycin (AMG) peak and trough serum levels were assigned by a group of pharmacokinetics experts, assuming prophylactic administration for laryngectomy interventions. A group of 27 adult patients, with normal renal function, undergoing elective surgery for laryngeal problems and treated prophylactically with gentamicin (80 mg t.i.d.) or tobramycin (100 mg t.i.d.) was studied. Two blood samples (peak and trough) were drawn at steady-state for AMG assay. Three different methods…

AdultMalemedicine.medical_specialtyDosePremedicationPopulationUrologyPharmacologyPharmacokineticsmedicineTobramycinHumansPharmacology (medical)educationSelection (genetic algorithm)Antibacterial agentAgedPharmacologyAged 80 and overeducation.field_of_studybusiness.industryClindamycinAminoglycosideMiddle AgedAnti-Bacterial AgentsOtorhinolaryngologic NeoplasmsTobramycinGentamicinFemaleGentamicinsbusinessmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers.

2006

AbstractTherapy of chronic respiratory diseases often involves inhalation therapy with nebulizers. Patients often attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. This article considers the issue of physico-chemical compatibility of admixtures of drug solutions/suspensions in nebulizers.A search of databases, prescribing information and primary literature was conducted to locate literature concerning the physico-chemical compatibility of inhalation solutions/suspensions. This was supplemented by telephone interviews.Admixtures of albuterol with ipratropium and/or cromolyn, of albuterol and budesonide, or tobramy…

BudesonideDrugPulmonary and Respiratory MedicineRespiratory TherapyCystic Fibrosismedia_common.quotation_subjectReviewCompatibilityBenzalkonium chlorideAdministration InhalationCromolyn SodiummedicineDeoxyribonuclease IHumansAlbuterolPediatrics Perinatology and Child HealthAnti-Asthmatic AgentsBudesonideFenoterolmedia_commonExpectorantsInhalationbusiness.industryColistinIpratropiumNebulizers and VaporizersNebulizerAsthmaAcetylcysteineAnti-Bacterial AgentsBronchodilator AgentsNebulizerInhalation solutionsAnesthesiaPediatrics Perinatology and Child HealthIpratropiumColistinTobramycinDrug Therapy Combinationbusinessmedicine.drugJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
researchProduct

Physiology and genetics of antibiotic production and resistance.

1993

Actinomycetes have the genetic capability to synthesize many different biologically active secondary metabolites and of these compounds, antibiotics predominate in therapeutic and commercial importance. Intensive research often centres on the use of molecular techniques to investigate the physiology and genetics of antibiotic biosynthesis with a view to improving production. The isolation of clones of Streptomyces hygroscopicus, the producer of geldanamycin, which synthesizes geldanamycin in S. lividans, is reported. Molecular approaches using genes for elongation factors (tuf) were used in attempts to increase the fermentation yield of kirromycin, whilst probes for aphD and sph, genes for …

Glycerolmedicine.drug_classPyridonesLactams MacrocyclicAntibioticsPhysiologyBiologySecondary metaboliteIn Vitro TechniquesMicrobiologychemistry.chemical_compoundActinomycetalesSpiramycinmedicineMolecular BiologyGeneGeneticsProdigiosinSpiramycinDrug Resistance MicrobialGeneral MedicineGeldanamycinbiology.organism_classificationStreptomycesAnti-Bacterial AgentschemistryBiochemistryStreptomycinTobramycinStreptomyces hygroscopicusBacteriamedicine.drugResearch in microbiology
researchProduct

Serial measurements of transient evoked otoacoustic emissions (TEOAEs) in healthy newborns and in newborns with perinatal infection.

1993

Detection of hearing impairment in early childhood is difficult. We serially recorded transient evoked otoacoustic emissions (TEOAEs) to search for signs of ototoxicity in term, healthy newborns and compared the results to a second group of term babies treated for perinatally acquired bacterial infection with ampicillin plus either cefotaxime or plus aminoglycoside. At initial evaluation, in the group of 45 healthy children born at term, well reproducible emissions were observed in all but two children. In each of these two, initially well reproducible TEOAEs were detected in one ear only. At the time of the second recording (mean at day 8.5) excellent emissions were seen in all ears of all…

MalePediatricsmedicine.medical_specialtyCefotaximeOtoacoustic emissionCefotaximeAudiologyOtotoxicityAmpicillinmedicineTobramycinHumansNetilmicinCochleabusiness.industryAminoglycosideInfant NewbornReproducibility of ResultsGeneral MedicineBacterial Infectionsmedicine.diseaseReflex AcousticAnti-Bacterial AgentsCochleaOtorhinolaryngologyPediatrics Perinatology and Child HealthAuditory PerceptionEvoked Potentials AuditoryTobramycinAmpicillinFemaleNetilmicinbusinessmedicine.drugFollow-Up StudiesInternational journal of pediatric otorhinolaryngology
researchProduct

In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneum…

2008

In this study, we compared the efficacy of ceftazidime (CAZ) intermittent versus continuous infusion with or without tobramycin (TOB) for the treatment of pneumonia caused by Pseudomonas aeruginosa in rabbits. Treatments were humanised and mimicked intermittent CAZ (iCAZ) (2g three times daily), continuous CAZ (cCAZ) (4g once daily (qd)) and TOB (10mg/kg qd). Minimum inhibitory concentrations (MICs) were 1mg/L and 4mg/L for TOB and CAZ, respectively. Bacterial efficacy in lungs was as follows: control, 9+/-0.6 colony-forming units (CFU)/g; TOB monotherapy, 8+/-0.5CFU/g; iCAZ monotherapy, 7.8+/-1.4CFU/g; cCAZ monotherapy, 8+/-0.4CFU/g (P = 0.005); and iCAZ+TOB, 8+/-0.5CFU/g; cCAZ+TOB, 7.2+/-…

Microbiology (medical)Malemedicine.drug_classAntibioticsColony Count MicrobialCeftazidimeMicrobial Sensitivity TestsCeftazidimeMicrobiologyPseudomonas infectionmedicineTobramycinPneumonia BacterialAnimalsHumansPharmacology (medical)Pseudomonas InfectionsInfusions IntravenousLungAntibacterial agentProtein synthesis inhibitorbusiness.industryAminoglycosideGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesPharmacodynamicsTobramycinDrug Therapy CombinationRabbitsbusinessSpleenmedicine.drugInternational journal of antimicrobial agents
researchProduct

Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy.

2002

ABSTRACT From 1992 to 1997, only six sporadic isolates of Salmonella enterica serotype Enteritidis from patients with cases of gastroenteritis in southern Italy exhibited resistance to broad-spectrum cephalosporins. Five isolates produced SHV-12, and one isolate encoded a class C β-lactamase. The bla SHV-12 gene was located in at least two different self-transferable plasmids, one of which also carried a novel class 1 integron.

Microbiology (medical)Serotypemedicine.drug_classEpidemiologySalmonella enteritidisCephalosporinIntegronbeta-LactamasesMicrobiologyPlasmidDrug Resistance Multiple BacterialGenotypemedicineHumansamoxicillin plus clavulanic acid; ampicillin; antibiotic agent; aztreonam; beta lactamase; cefotaxime; cefoxitin; ceftazidime; cephalosporin derivative; chloramphenicol; kanamycin; plasmid DNA; streptomycin; sulfonamide; tobramycin antibiotic resistance; article; bacterial infection; bacterium isolate; DNA probe; gastroenteritis; gastrointestinal infection; Italy; nonhuman; nucleotide sequence; phenotype; plasmid; priority journal; Salmonella; Salmonella enterica Base Sequence; beta-Lactamases; Cephalosporin Resistance; Cross Infection; Drug Resistance Multiple Bacterial; Gastroenteritis; Genes Bacterial; Humans; Italy; Plasmids; Salmonella enteritidis; Salmonella Infections Bacteria (microorganisms); Negibacteria; Salmonella; Salmonella entericaCephalosporin ResistanceCross InfectionbiologyBase SequenceCephalosporin Resistancebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationVirologyGastroenteritisItalySalmonella enteritidisSalmonella entericaGenes BacterialSalmonella Infectionsbiology.proteinPlasmidsJournal of clinical microbiology
researchProduct

Polyaspartamide based microparticles for Tobramycin delivery to the lung in FC therapy

2015

PolyaspartamidemicroparticlesTobramycin Polyaspartamide microparticles FC therapyFC therapyTobramycin; Polyaspartamide; microparticles; FC therapyTobramycin
researchProduct